Rheumatol Ther. 2023 doi 10.1007/s40744-023-00594-6 Epub ahead of print
This study by Harrold, et al. showed that RA patients initiating upadacitinib reported improvements in RAPID3, pain, stiffness, and fatigue as early as Week 1, with 37.5% achieving RAPID3 LDA at Week 12. TNFi-experienced patients had similar outcomes.
PROs were assessed over a 12-week period via a mobile health app. These real-world data suggest that upadacitinib leads to early and significant improvements in RA symptoms, with high patient-reported medication convenience.